Clinical trialsCompany release

Vivani reports $7.3M Q3 loss as semaglutide implant data near

🇺🇸 Vivani Medical, Inc. (VANI) · Thu 12 Nov 2026

Vivani Medical says top-line Phase 1 data for its NPM-139 semaglutide implant are due this week, while the Cortigent merger still awaits final regulatory approvals.

Vivani Medical reported its third-quarter 2026 results on 11 November, showing a net loss of $7.3 million and cash of $15.5 million.

The company said top-line data from the Phase 1 SLIM-1 trial are expected later this week. The study is testing NPM-139, a semaglutide implant intended for chronic weight management, against starting-dose Wegovy in 20 participants in Australia.

Vivani also said its merger of Cortigent and ClearOne has not yet closed and is still waiting on final regulatory approvals. No further detail on the approvals or timing was available in the material reviewed.

Looking ahead, the company plans to file an Investigational New Drug (IND) application for a Phase 2 study of NPM-139 in 2027. An IND application is the filing a sponsor submits to the US Food and Drug Administration before starting clinical trials in the US.

What it means for your team

  • Teams tracking long-acting GLP-1 delivery should watch this week's SLIM-1 top-line readout, which is a small Phase 1 comparison against starting-dose Wegovy.
  • A Phase 2 IND is planned for 2027, so US clinical development of NPM-139 is not expected to progress before then.
  • The Cortigent-ClearOne merger remains subject to final regulatory approvals, so its completion should not be assumed.

Company's press release (SEC filing): Vivani Medical, Inc. ↗

Article written by VigiEye from the official source (Vivani Medical, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →